Main Article Content


Dermatomyositis is an idiopathic inflammatory myopathy characterized by the presence of rash and moderate-to-severe muscle weakness secondary to inflammation of the muscle. It can be a difficult condition to treat. Systemic corticosteroids are the first choice of treatment. However, about a quarter of patients either fail to respond to steroids or develop steroid-related toxicity. Second-line agents such as azathioprine and methotrexate are then added either alone, or in combination with corticosteroids. Failure of the disease to respond to
second-line agents can then be a problem and this is often referred to as “refractory dermatomyositisâ€. Unfortunately, there is neither agreement nor wellestablished guidelines on the best regimen or combination of immunosuppressive agents in the case of refractory dermatomyositis.

Article Details

How to Cite
Setiyohadi, B., & Sinto, R. (2018). Experience with cyclophosphamide in the treatment of a young woman with refractory dermatomyositis. Indonesian Journal of Rheumatology, 3(1).


  1. Bernatsky S, Joseph L, Pineau CA, Bélisle P, Boivin JF, Banerjee D, et al. Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis. 2009; 68: 1192–6.
  2. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 71–82.
  3. Bendewald MJ, Wetter DA, Li X, Davis MDP. Incidence of dermatomyositis and clinically amyopathic dermatomyositis. Arch Dermatol. 2010; 146: 26–30.
  4. Wortmann RL. Idiopathic infl ammatory myopathies: clinical features. In: Klippel JH, Stone JH, Crofford LJ, White PH, editors. Primer on the rheumatic disease. 13th ed. New York: Springer; 2008. p. 363–7.
  5. Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis:a review of effi cacy and safety. Rheumatology 2004: 43: 491–6.
  6. Ponyi A, Borgulya G, Constantin T, Vancsa A, Gergely L, Danko K. Functional outcome and quality of life in adult patients with idiopathic infl ammatory myositis. Rheumatology 2005; 44: 83–88.
  7. Oddis CV. Idiopathic infl ammatory myopathies: treatment and assessment. In: Klippel JH, Stone JH, Crofford LJ, White PH, editors. Primer on the rheumatic disease. 13th ed. New York: Springer; 2008. p.375–80.
  8. Cordeiro AC, Isenberg DA. Treatment of infl ammatory myopathies.Postgrad Med J. 2006; 82: 417–24.
  9. Lundberg IE, Vencovsky J, Dani L. Polymostitis, dermatomyositis, infl ammatory diseases of muscle and other myopathies. In: Bijlsma JWJ, Burmester GR, Silva JAP, Faarvang KL, Hachulla E, Mariette X. Eular compedium on rheumatic diseases. 1st ed. Kilchberg: BMJ Publishing Group; 2009. p. 297–313.
  10. McCann LJ, Garay SM, Ryan MM, Harris R, Riley P, Pilkington CA. Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofl uoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. Rheumatology 2007; 46: 1363–6.
  11. Oh TH, Brumfi eld KA, Hoskin TL, Stolp KA, Murray JA, Basford JR. Dysphagia in infl ammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc. 2007; 82 : 441–7.
  12. Whallett AJ, Gillott TJ, Klocke R, Coppock JS. A case of refractory adult dermatomyositis. Br J Rheumatol 1998; 37: 544–5.
  13. Rider LG, Miller FW. Deciphering the clinical presentations, pathogenesis,
  14. and treatment of the idiopathic infl ammatory myopathies. JAMA 2011; 305: 183–90.
  15. Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/ dermatomyositis. rheumatology 2007; 46: 124–30.
  16. Choy EHS, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology 2002; 41: 7–13.
  17. Katsifi s GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus 2004; 13: 673–8.
  18. Martin-Suarez I, Cruz DD, Mansoor M, Fernandes AP, Khamashta MA, Hughes GRV. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis. 1997; 56: 481–7.
  19. Martin F, Lauwerys B, Lefebvre C, Devogelaer JP, Houssiau. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 1997; 6: 254–7.
  20. Chen IJ, Tsai WP, Wu YJJ, Luo SF, Ho HH, Liou LB, et al. Infections in polymyositis and dermatomyositis: analysis of 192 cases. Rheumatology 2010; 49: 2429–37.
  21. Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B. Polymyositis and dermatomyositis: short-term and long-term outcome, and predictive factors of prognosis. J Rheumatol 2001; 28: 2230–7